Cytokinetics, Incorporated
CYTK
$31.70
-$0.785-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 412.21% | 145.34% | -58.81% | -68.51% | -66.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 412.21% | 145.34% | -58.81% | -68.51% | -96.17% |
| Cost of Revenue | 7.65% | 2.81% | 3.31% | 9.42% | 21.13% |
| Gross Profit | -3.03% | 0.51% | -4.86% | -12.10% | -86.40% |
| SG&A Expenses | 34.07% | 24.02% | 7.43% | -5.76% | -12.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.57% | 10.12% | 4.81% | 3.51% | 7.01% |
| Operating Income | -13.59% | -8.07% | -5.81% | -5.00% | -34.29% |
| Income Before Tax | -15.96% | -12.03% | -9.43% | -1.05% | -23.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.96% | -12.03% | -9.43% | -1.05% | -23.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.96% | -12.03% | -9.43% | -1.05% | -23.17% |
| EBIT | -13.59% | -8.07% | -5.81% | -5.00% | -34.29% |
| EBITDA | -14.53% | -8.76% | -4.61% | -3.78% | -33.22% |
| EPS Basic | 1.75% | 3.20% | 2.39% | 5.62% | -17.98% |
| Normalized Basic EPS | 1.75% | 3.20% | 2.40% | 1.52% | -24.43% |
| EPS Diluted | 1.75% | 3.20% | 2.39% | 5.62% | -17.98% |
| Normalized Diluted EPS | 1.75% | 3.20% | 2.40% | 1.52% | -24.43% |
| Average Basic Shares Outstanding | 17.99% | 15.77% | 12.12% | 7.10% | 6.36% |
| Average Diluted Shares Outstanding | 17.99% | 15.77% | 12.12% | 7.10% | 6.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |